Drawing for UNIQURE

USPTO serial 85907857

UNIQURE

Reviewed by CopyMark Law Group

Reg. 4710280Status 800Registered
Filing date
Status date
Registration date
Mar 31, 2015
Examiner
LEVINE, HOWARD B
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.

Status 800: Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection.

Need help with UNIQURE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Julianne Abelman

Julianne Abelman ABELMAN LAW PLLC16 Sutton Place, Suite 5BNew York, NY 10022United States

Goods and services

ClassDescriptionStatusFirst use
001[Viral assays, viral reagents, viral preparations, gene therapy assays, gene therapy reagents, gene therapy preparations, nucleic acid delivery assays, nucleic acid delivery reagents, nucleic acid delivery preparations, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors, all for non-medical research purposes]SECTION 8 - CANCELLED—
005Viral medicines, gene therapy medicines, nucleic acid delivery medicines, viral vectors, [non-viral vectors,] gene therapy vectors, nucleic acid delivery vectors, [and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors] for medical purposes all for medical treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers;] pharmaceutical preparations and substances for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers;] biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy [and cell therapy,] all for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,]inherited disorders, genetic disorders, single gene disorders [and cancers;] [clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing in the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; pharmaceutical preparations, vaccines, prophylaxis medicines and other] pharmaceutical preparations [all] for use in nucleic acid-based therapy, gene therapy [and cell therapy] in the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers]ACTIVE—
042Research, product development and consultancy in the field of biotechnology, biologics, pharmaceutics, medical science, chemistry and biochemistryACTIVE—
044Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders,] inherited disorders, genetic disorders and single gene disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 11, 2025ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jun 4, 2025EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Jun 4, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 4, 2025ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jun 4, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 4, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 4, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jun 4, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jan 27, 2025NA89NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED—
Jan 27, 2025RNL1REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active.
Jan 27, 202589AGREGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTEDThe USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary.
Jan 27, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 4, 2024E89RTEAS SECTION 8 & 9 RECEIVED—
Mar 31, 2024REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Apr 1, 2021NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Apr 1, 2021C15PREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Nov 10, 2020APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Sep 17, 2020E815TEAS SECTION 8 & 15 RECEIVED—
Mar 31, 2020REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Mar 31, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 18, 2014DP1B1(B) BASIS DELETED; PROCEED TO REGISTRATION—
Nov 18, 2014AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Oct 29, 2014IUCNNOTICE OF ALLOWANCE CANCELLED—
Oct 29, 2014D1BRTEAS DELETE 1(B) BASIS RECEIVED—
Oct 28, 2014NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 2, 2014NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 2, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 13, 2014NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 28, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 28, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 24, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 24, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 24, 2014ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Feb 22, 2014GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Feb 22, 2014GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 22, 2014CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jan 31, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 31, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 26, 2014ALIEASSIGNED TO LIE—
Jan 16, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 16, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 5, 2013GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 5, 2013GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 5, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 5, 2013DOCKASSIGNED TO EXAMINER—
Apr 25, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 22, 2013NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance